Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Assets (2023 - 2025)

Monte Rosa Therapeutics' Current Assets history spans 3 years, with the latest figure at $393.2 million for Q4 2025.

  • For Q4 2025, Current Assets rose 4.17% year-over-year to $393.2 million; the TTM value through Dec 2025 reached $393.2 million, up 4.17%, while the annual FY2025 figure was $393.2 million, 4.17% up from the prior year.
  • Current Assets reached $393.2 million in Q4 2025 per GLUE's latest filing, down from $401.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $401.8 million in Q3 2025 to a low of $182.9 million in Q3 2023.
  • Average Current Assets over 3 years is $283.3 million, with a median of $264.6 million recorded in 2024.
  • Peak YoY movement for Current Assets: decreased 17.26% in 2024, then soared 66.94% in 2025.
  • A 3-year view of Current Assets shows it stood at $236.2 million in 2023, then surged by 59.79% to $377.4 million in 2024, then increased by 4.17% to $393.2 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Current Assets are $393.2 million (Q4 2025), $401.8 million (Q3 2025), and $299.5 million (Q2 2025).